The pharmacokinetics of the alanine-containing DOTA-conjugated PSMA inhibitor, PSMA-617, labeled with 111In, on the other hand, was excellent with impressive tumor to background ratios over time. This evidence concerns the gene FOLH1 and neoplasm.